CABOXEN-20MG (Cabozantinib): Uses, Dosage, Side Effects & Cancer Treatment
What Is CABOXEN-20MG?
CABOXEN-20MG contains cabozantinib, a targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class.
Cabozantinib acts on several signalling proteins involved in cancer-cell growth, tumour development and the formation of blood vessels that can supply tumours.
Depending on the regulatory jurisdiction and specific formulation, cabozantinib is used in the treatment of several advanced cancers. Current EMA information includes indications involving advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and certain unresectable or metastatic neuroendocrine tumours.
The product details provided are:
- Product Name: CABOXEN-20MG
- Generic Name: Cabozantinib
- Strength: 20 mg
- Dosage Form: Capsules
- Pack Size: 90 Capsules
Cabozantinib is a prescription oncology medicine and should be used under the supervision of a qualified cancer specialist.
What Is Cabozantinib Used For?
Cabozantinib has multiple oncology applications depending on the formulation, country-specific approval and clinical situation.
According to current EMA information, Cabometyx (cabozantinib) is indicated for several adult cancer settings.
Renal Cell Carcinoma
Cabozantinib may be used for adults with advanced renal cell carcinoma.
It can be used:
- As first-line treatment in adults with intermediate- or poor-risk advanced RCC.
- Following previous VEGF-targeted therapy.
- In combination with nivolumab as first-line treatment for advanced RCC in adults.
Hepatocellular Carcinoma
Cabozantinib is indicated for adults with hepatocellular carcinoma who have previously received sorafenib.
Differentiated Thyroid Carcinoma
Cabozantinib is also used for certain adults with locally advanced or metastatic differentiated thyroid carcinoma that has progressed during or after previous systemic treatment and is refractory to radioactive iodine or unsuitable for radioactive iodine therapy.
Neuroendocrine Tumours
Current EMA information also includes treatment of adults with unresectable or metastatic, well-differentiated pancreatic or extra-pancreatic neuroendocrine tumours following at least one previous systemic therapy other than somatostatin analogues.
How Does Cabozantinib Work?
Cancer growth depends on complex biological signalling pathways. Some signalling proteins stimulate cancer-cell proliferation, survival, migration and the development of new blood vessels.
Cabozantinib is a tyrosine kinase inhibitor. It blocks the activity of selected receptor tyrosine kinases involved in tumour biology.
Important molecular targets include signalling pathways involving receptors such as:
- VEGFR
- MET
- AXL
- RET
By inhibiting these pathways, cabozantinib can interfere with signals that support tumour growth and angiogenesis.
A simplified biological pathway can be represented as:
Cancer-associated signalling → receptor activation → tumour-cell growth + angiogenesis → tumour progression
Cabozantinib works by interfering with selected receptor tyrosine kinases:
Cabozantinib → receptor tyrosine kinase inhibition → reduced growth signalling + reduced angiogenic signalling → inhibition of tumour progression
The EMA describes cabozantinib as a tyrosine kinase inhibitor that blocks enzymes involved in processes including cell division and the growth of new blood vessels supplying cancer cells.
This multi-target mechanism is one reason cabozantinib has applications across several tumour types.
Key Indications
Advanced Renal Cell Carcinoma
Cabozantinib is used in specific adults with advanced kidney cancer.
It may be prescribed alone or, in an approved first-line setting, together with nivolumab.
Hepatocellular Carcinoma
Cabozantinib can be used for adults with HCC who have previously received sorafenib.
Differentiated Thyroid Carcinoma
It is used for certain patients with locally advanced or metastatic differentiated thyroid cancer following previous systemic treatment when radioactive iodine is not appropriate or the disease is resistant to it.
Neuroendocrine Tumours
Cabozantinib has an EMA indication for selected adults with unresectable or metastatic, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumours after previous systemic therapy.
Cabozantinib Dosage and Administration
Important: Cabozantinib dosing depends on the indication, formulation and combination treatment.
Current EMA product information for Cabometyx tablets lists:
- 60 mg once daily for monotherapy in RCC, HCC, DTC and NET.
- 40 mg once daily when used with nivolumab for first-line advanced RCC.
Therefore, CABOXEN-20MG should not automatically be interpreted as a 20 mg daily treatment dose. The appropriate regimen must be prescribed according to the patient's cancer type, treatment history, formulation and clinical condition.
Administration Guidance
For Cabometyx tablets, EMA guidance states that the medicine is taken orally once daily and patients should not eat for at least 2 hours before and 1 hour after taking it.
Patients should:
- Follow the oncologist's prescribed dose.
- Take the medicine consistently at approximately the same time.
- Follow formulation-specific administration instructions.
- Avoid changing the dose independently.
- Continue treatment only as directed by the treating specialist.
Dose Modification
Dose interruption or reduction may be required when significant or unacceptable adverse effects develop.
Missed Dose
If a dose is missed, patients should follow the instructions provided by their healthcare professional or the specific product information.
Do not double the next dose unless specifically instructed.
Cabozantinib Side Effects
Cabozantinib can cause adverse reactions, and some require regular monitoring.
Common Side Effects
Commonly reported effects include:
- Diarrhea
- Fatigue
- Nausea
- Reduced appetite
- High blood pressure
- Hand-foot syndrome
- Vomiting
- Weight loss
- Weakness
The exact adverse-effect profile varies according to tumour type and treatment combination.
Less Common Side Effects
Other reactions can include:
- Abdominal pain
- Dehydration
- Electrolyte abnormalities
- Changes in liver function
- Changes in blood counts
- Dizziness
- Mouth-related problems
- Skin reactions
Serious Side Effects
Potential serious complications can include:
- Severe hypertension
- Gastrointestinal complications
- Blood clots
- Pulmonary embolism
- Severe diarrhea
- Pneumonia
- Significant dehydration
- Liver-related complications
- Serious bleeding
- Jaw osteonecrosis in certain treatment settings
The EMA lists several serious adverse reactions that vary by indication.
When to Seek Medical Attention
Prompt medical evaluation may be necessary for:
- Severe or persistent diarrhea
- Significant bleeding
- Severe abdominal pain
- Difficulty breathing
- Chest pain
- Sudden weakness
- Severe headache or very high blood pressure
- Signs of dehydration
- Severe skin reactions
- New neurological symptoms
Drug Interactions
Cabozantinib can interact with other medicines and substances.
Medicines Requiring Monitoring
Particular caution may be required with medicines that:
- Affect CYP3A4 activity
- Alter cabozantinib exposure
- Increase bleeding risk
- Affect blood pressure
- Influence cardiac rhythm
A complete medication list should be reviewed by the treating oncology team.
Food Considerations
For Cabometyx tablets, patients should avoid food for at least 2 hours before and 1 hour after administration.
Always follow the instructions applicable to the exact cabozantinib formulation being prescribed.
Supplement Considerations
Patients should inform their doctor about:
- Herbal medicines
- Traditional remedies
- Vitamins
- High-dose supplements
- Unregulated cancer products
Do not begin a new supplement without discussing it with the oncology team.
Warnings and Precautions
Bleeding Risk
Cabozantinib may increase the risk of clinically significant bleeding in susceptible patients.
Patients should report unusual or persistent bleeding.
Blood Pressure
Hypertension is a common adverse reaction and may become clinically significant.
Blood pressure should be monitored during treatment.
Gastrointestinal Considerations
Diarrhea, nausea, vomiting and abdominal symptoms can occur. Severe gastrointestinal toxicity can lead to dehydration and other complications.
Cardiovascular Considerations
Patients with cardiovascular disease or risk factors should be evaluated carefully before and during therapy.
Liver Considerations
Cabozantinib is used in patients with certain liver cancers, but hepatic function remains clinically important. Monitoring may be required depending on the patient's condition and concomitant medicines.
Wound Healing
Cabozantinib can affect wound healing. The treating physician may provide specific instructions around major surgery.
Jaw and Dental Considerations
Osteonecrosis of the jaw has been reported, particularly in certain cancer-treatment settings. Dental health should be discussed with the treating team before and during therapy.
Pregnancy and Breastfeeding
Cabozantinib may cause fetal harm based on its pharmacological properties and available safety information.
Patients who are pregnant, planning pregnancy or capable of becoming pregnant should discuss treatment and contraception with their healthcare professional.
Breastfeeding should be discussed with the treating physician. Patients should follow the applicable product information for their specific formulation and jurisdiction.
Special Populations
Elderly Patients
Older adults may receive cabozantinib when clinically appropriate. Treatment decisions should consider:
- Overall health
- Kidney and liver function
- Cardiovascular status
- Concomitant medicines
- Treatment tolerance
Pediatric Patients
Cabozantinib is not automatically interchangeable between adult and pediatric indications. Pediatric use should be determined by an appropriate specialist under an approved indication.
Renal Impairment
Patients with kidney impairment should inform their physician before starting treatment. Individual assessment and monitoring may be required.
Hepatic Impairment
Liver function can influence treatment decisions. Patients with hepatic impairment require individualized assessment by their oncology team.
Storage of CABOXEN-20MG
Store CABOXEN-20MG according to the specific storage instructions provided on its packaging.
General precautions include:
- Keep the medicine in its original packaging.
- Protect it from unsuitable heat and moisture.
- Keep it out of reach of children.
- Do not use damaged or visibly altered capsules.
- Follow the storage temperature stated on the product label.
Frequently Asked Questions About CABOXEN-20MG
1. What is CABOXEN-20MG used for?
CABOXEN-20MG contains cabozantinib, a targeted anticancer medicine used in specific treatment settings for advanced cancers.
2. What is cabozantinib?
Cabozantinib is a multi-target tyrosine kinase inhibitor used in several oncology indications.
3. Is cabozantinib chemotherapy?
Cabozantinib is a targeted tyrosine kinase inhibitor rather than conventional cytotoxic chemotherapy.
4. How does cabozantinib work?
It blocks selected receptor tyrosine kinases involved in tumour growth, signalling and angiogenesis.
5. Is cabozantinib used for kidney cancer?
Yes. It is used in specific adults with advanced renal cell carcinoma.
6. Is cabozantinib used for liver cancer?
Yes. Cabozantinib is indicated for certain adults with hepatocellular carcinoma who have previously received sorafenib.
7. Is cabozantinib used for thyroid cancer?
Yes. It is used for selected adults with locally advanced or metastatic differentiated thyroid carcinoma under approved conditions.
8. What are common cabozantinib side effects?
Diarrhea, fatigue, nausea, reduced appetite, hand-foot syndrome and hypertension are among commonly reported effects.
9. Can cabozantinib cause high blood pressure?
Yes. Hypertension is a recognized adverse effect and blood pressure monitoring may be required.
10. Can cabozantinib cause diarrhea?
Yes. Diarrhea is common and can sometimes become clinically significant.
11. Can cabozantinib cause bleeding?
Serious bleeding can occur, so patients should report unusual bleeding promptly.
12. Can cabozantinib be taken with food?
For Cabometyx tablets, food should be avoided for at least 2 hours before and 1 hour after administration.
13. Is cabozantinib a targeted therapy?
Yes. It is a targeted tyrosine kinase inhibitor that interferes with selected cancer-related signalling pathways.
14. Can cabozantinib cure cancer?
It should not be described as a guaranteed cure. It is a treatment intended to control or delay progression of specific cancers in appropriate patients.
15. Should cabozantinib be taken without a prescription?
No. Cabozantinib is a prescription oncology medicine and treatment should be supervised by an experienced cancer specialist.
Global Medicine Information & Support by RootAid Pharma
RootAid Pharma provides pharmaceutical information and specialty-medicine support for individuals and organizations seeking information about prescription and high-value medicines.
Our information resources cover:
- Oncology medicines
- Targeted cancer therapies
- Kidney cancer medicines
- Liver cancer medicines
- Thyroid cancer treatments
- Neuroendocrine tumour medicines
- Generic and brand medicine information
- Treatment-related information
- Prescription support
- International medicine information
For medicines such as cabozantinib, treatment should be managed by a qualified oncologist or other appropriately trained healthcare professional.
RootAid Pharma does not claim to manufacture CABOXEN-20MG or cabozantinib. Medicine availability, prescription requirements, import regulations and local laws may differ between countries.
Medical Disclaimer
This article is intended for general educational and informational purposes only. It does not replace professional medical advice, diagnosis, prescribing information or individualized cancer treatment.
Cabozantinib is a prescription anticancer medicine. The correct dose and treatment schedule depend on the specific indication, formulation, previous treatment, patient characteristics and clinical response.
Approved indications and prescribing recommendations may vary between countries and may change as regulatory information is updated.
Do not start, stop, increase or reduce cabozantinib without guidance from a qualified healthcare professional.
Need help after reading this?
Talk to our support team for sourcing guidance, product availability, and global delivery assistance.